Verification evidence is still being completed.
PDF / print export
Tubulis GmbH
Planegg-Martinsried, Germany
- Verified lead
- Dominik Schumacher
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Managing Director
- 2026 technical specialization
- Antibody-Drug Conjugates, P5 Conjugation Platform, and Solid Tumor Oncology
- Review cycle
- 24 April 2026
- Full address
- Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Tubulis imprint listing Dominik Schumacher and Jonas Helma-Smets as joint Managing Directors.
- Editorial note
- Planegg-Martinsried ADC biotech with named co-founder CEO, proprietary P5 conjugation platform, tubutecan payload class, and an approximately 308 million euro Series C financing announced in 2025.
Antibody-Drug Conjugates, P5 Conjugation Platform, and Solid Tumor Oncology
Public joint managing directors disclosure, Handelsregister record HRB 249942, Documented Series C 2025 financing
Planegg-Martinsried ADC biotech with named co-founder CEO, proprietary P5 conjugation platform, tubutecan payload class, and an approximately 308 million euro Series C financing announced in 2025.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Planegg-Martinsried, Germany
Tubulis GmbH
Antibody-Drug Conjugates, P5 Conjugation Platform, and Solid Tumor Oncology · Research to clinical-stage ADC development
Planegg-Martinsried ADC biotech with named co-founder CEO, proprietary P5 conjugation platform, tubutecan payload class, and an approximately 308 million euro Series C financing announced in 2025.
- Lead
- Dominik Schumacher (verified ↗)
- Address
- Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Research to clinical-stage ADC development
- Capabilities
- P5 Conjugation Platform · Tubutecan Payload Class · Clinical ADC Development
- Founded
- 2019
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Dominik Schumacher
Chief Executive Officer and Managing Director
Full addressAm Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
North Data HRB 249942 record listing Am Klopferspitz 19a in Planegg-Martinsried.
Open sourceResearch to clinical-stage ADC development
Planegg-Martinsried, Germany. Antibody-Drug Conjugates, P5 Conjugation Platform, and Solid Tumor Oncology. Review completed on 24 Apr 2026.
BfArM and EMA for clinical oversight
Public joint managing directors disclosure, Handelsregister record HRB 249942, Documented Series C 2025 financing
Antibody-Drug Conjugates, P5 Conjugation Platform, and Solid Tumor Oncology
Planegg-Martinsried ADC biotech with named co-founder CEO, proprietary P5 conjugation platform, tubutecan payload class, and an approximately 308 million euro Series C financing announced in 2025.
Editorial note
Tubulis is a Planegg-Martinsried ADC biotech with named co-founder management, a proprietary P5 conjugation platform, and a 2025 Series C financing of around 308 million euros supporting late-preclinical and clinical advancement of TUB-040.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
P5 Conjugation Platform
Tubutecan Payload Class
Clinical ADC Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
ADC design and characterization workflows
Partner CDMO GMP conjugation
Clinical-trial operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Tubulis GmbH located?
- Tubulis GmbH operates from Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany, Planegg-Martinsried, Germany.
- Who runs Tubulis GmbH?
- Tubulis GmbH is led by Dominik Schumacher, Chief Executive Officer and Managing Director. Verified 24 Apr 2026.
- What does Tubulis GmbH do?
- Planegg-Martinsried ADC biotech with named co-founder CEO, proprietary P5 conjugation platform, tubutecan payload class, and an approximately 308 million euro Series C financing announced in 2025. Core capabilities: P5 Conjugation Platform, Tubutecan Payload Class, Clinical ADC Development.
Editorial context
Related technical briefs
Briefs that name Planegg-Martinsried as a covered market or city.